FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats

Journal of Lipid Research

Volumn 51, Issue 4, 2010, Pages 771-784

  Cipriani, Sabrina ^a   Mencarelli, Andrea ^a   Palladino, Giuseppe ^a   Fiorucci, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 ETHYL CHENODEOXYCHOLIC ACID; CELL NUCLEUS RECEPTOR; CHENODEOXYCHOLIC ACID DERIVATIVE; FARNESOID X RECEPTOR; HIGH DENSITY LIPOPROTEIN; INSULIN RECEPTOR SUBSTRATE 1; ROSIGLITAZONE; SERINE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 6-ETHYLCHENODEOXYCHOLIC ACID; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CELL RECEPTOR; CHENODEOXYCHOLIC ACID; FARNESOID X-ACTIVATED RECEPTOR; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, RAT; LIPID; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; FATTY ACID SYNTHESIS; FATTY LIVER; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIVER; MALE; MUSCLE TISSUE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; ZUCKER RAT; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; COMPARATIVE STUDY; COMPLICATION; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RANDOMIZATION; SKELETAL MUSCLE; TIME;

ANIMALS; CHENODEOXYCHOLIC ACID; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FATTY LIVER; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; LIVER; MALE; MUSCLE, SKELETAL; OBESITY; PHOSPHORYLATION; RANDOM ALLOCATION; RATS; RATS, ZUCKER; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 77950613528     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M001602     Document Type: Article

References (39)

1. Varela-Rey, M., N. Embade, U. Ariz, S. C. Lu, J. M. Mato, and M. L Martìnez-Chantar. 2009. Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int. J. Biochem. Cell Biol. 41: 969-976.
2. Adams, L. A., and P. Angulo. 2006. Treatment of non-alcoholic fatty liver disease. Postgrad. Med. J. 82: 315-322.
3. Hotamisligil, G. S., D. L. Murray, L. N. Choy, and B. M. Spiegelman. 2004. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. USA. 91: 4854-4858.
4. Kanety, H., R. Feinstein, M. Z. Papa, R. Hemi, and A. Karasik. 1995. Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin stimulated tyrosine phosphorylation of IRS-1. J. Biol. Chem. 270: 23780-23784.
5. Paz, K., R. Hemi, D. Leroith, A. Karasik, E. Elhanany, H. Kanety, and Y. Zick. 1997. A molecular basis for insulin resistance. Elevated serine threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phospho-rylation. J. Biol. Chem. 272: 29911-29918.
6. Zick, Y. 2001. Insulin resistance: a phosphorylation-based uncou-pling of insulin signalling. Trends Cell Biol. 11: 437-441.
7. Kahn, S. E., R. L. Hull, and K. M. Utzscheneider. 2006. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 444: 840-846.
8. Guilherme, A., J. V. Virbasius, V. Puri, and M. P. Czech. 2008. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 9: 367-377.
9. Fiorucci, S., G. Rizzo, A. Donini, E. Distrutti, and L. Santucci. 2007. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med. 13: 298-309.
10. Cariou, B. 2008. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. Diabetes Metab. 34: 685-691.
11. Rizzo, G., M. Disante, A. Mencarelli, B. Renga, A. Gioiello, R. Pellicciari, and S. Fiorucci. 2006. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol. Pharmacol. 70: 1164-1173.
12. Zhang, Y., F. Y. Lee, G. Barrera, H. Lee, C. Vales, F. J. Gonzalez, T. M. Willson, and P. A. Edwards. 2006. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. USA. 103: 1006-1011.
13. Duran-Sandoval, D., B. Cariou, F. Percevault, N. Hennuyer, A. Grefhorst, T. H. van Dijk, F. J. Gonzalez, J. C. Fruchart, F. Kuipers, and B. Staels. 2005. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J. Biol. Chem. 280: 29971-29979.
14. Shen, H., Y. Zhang, H. Ding, X. Wang, L. Chen, H. Jiang, and X. Shen. 2008. Farnesoid X Receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter. Cell. Physiol. Biochem. 22: 01-14.
15. Durham, H. A., and G. E. Truett. 2006. Development of insulin resistance and hyperphagia in Zucker fatty rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290: R652-R658.
16. Larter, C. Z., and M. M. Yeh. 2008. Animal models of NASH: get-ting both pathology and metabolic context right. J. Gastroenterol. Hepatol. 23: 1635-1648.
17. George, J., and C. Liddle. 2008. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol. Pharm. 5: 49-59.
18. Cho, N., and Y. Momose. 2008. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Curr. Top. Med. Chem. 8: 1483-1507
19. Scarpello, J.H.,and H. C. Howlett. 2008. Metformin therapy and clinical uses. Diab. Vasc. Dis. Res. 5: 157-167.
20. Fiorucci, S., A. Mencarelli, E. Distrutti, G. Palladino, and S. Cipriani. 2009. Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. Curr. Med. Chem. Epub ahead of print. November 24, 2009.
21. Fiorucci, S., E. Antonelli, G. Rizzo, B. Renga, A. Mencarelli, L. Riccardi, S. Orlandi, R. Pellicciari, and A. Morelli. 2004. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fi brosis. Gastroenterology. 127: 1497-1512.
22. Yu, C., Y. Chen, G. W. Cline, D. Zhang, H. Zong, Y. Wang, R. Bergeron, J. K. Kim, S. W. Cushman, G. J. Cooney, et al. 2002. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277: 50230-50236.
23. Shulman, G. I. 2000. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106: 171-176 (Review).
24. Hotamisligil, G. S. 1999. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J. Intern. Med. 245: 621-625.
25. Cariou, B., K. van Harmelen, D. Duran-Sandoval, T. H. van Dijk, A. Grefhorst, M. Abdelkarim, S. Caron, G. Torpier, J. C. Fruchart, F. J. Gonzalez, et al. 2006. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 281: 11039-11049.
26. Wang, J., I. Leclercq, J. M. Brymora, N. Xu, M. Ramezani-Moghadam, R. M. London, D. Brigstock, and J. George. 2009. Kupffer cells mediate leptin-induced liver fi brosis. J. Gastroenterol. 137: 713-723.
27. Shulman, A. I., and D. J. Mangelsdorf. 2005. Retinoid x receptor het-erodimers in the metabolic syndrome. N. Engl. J. Med. 353: 604-615.
28. Aithal, G. P., J. A. Thomas, P. V. Kaye, A. Lawson, S. D. Ryder, I. Spendlove, A. S. Austin, J. M. Freeman, L. Morgan, and J. Webber. 2008. Randomized, placebo-controlled trial of pioglitazone in non-diabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 135: 1176-1184.
29. García-Ruiz, I., C. Rodríguez-Juan, T. Díaz- Sanjuán, M. A. Martinez, T. Muñoz-Yagüe, and J. A. Solís-Herruzo. 2007. Effects of rosiglita-zone on the liver histology and mitochondrial function in ob/ob mice. Hepatology. 46: 414-423.
30. Sharma, A. M., and B. Staels. 2007. Peroxisome proliferator-acti-vated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J. Clin. Endocrinol. Metab. 92: 386-395.
31. Watanabe, M., S. M. Houten, L. Wang, A. Moschetta, D. J. Mangelsdorf, R. A. Heyman, D. D. Moore, and J. Auwerx. 2004. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 113: 1408-1418.
32. Ma, K., P. K. Saha, L. Chan, and D. D. Moore. 2006. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 116: 1102-1109.
33. Savkur, R. S., K. S. Bramlett, L. F. Michael, and T. P. Burris. 2005. Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor. Biochem. Biophys. Res. Commun. 329: 391-396.
34. Zhang, Y., L. W. Castellani, C. J. Sinal, F. J. Gonzalez, and P. A. Edwards. 2004. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev. 18: 157-169.
35. Fiorucci, S., and F. Baldelli. 2009. Farnesoid X receptor agonists in biliary tract disease. Curr. Opin. Gastroenterol. 25: 252-259.
36. Chiang, J. Y. L. 2009. Bile acids: regulation of synthesis. J. Lipid Res. 50: 1955-1966.
37. Fiorucci, S., C. Clerici, E. Antonelli, S. Orlandi, B. Goodwin, B. M. Sadeghpour, G. Sabatino, G. Russo, D. Castellani, T. M. Willson, et al. 2005. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J. Pharmacol. Exp. Ther. 313: 604-612.
38. Moschetta, A., A. L. Bookout, and D. J. Mangelsdorf. 2004. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat. Med. 10: 1352-1358.
39. Claudel, T., E. Sturm, H. Duez, I. P. Torra, A. Sirvent, V. Kosykh, J. C. Fruchart, J. Dallongeville, D. W. Hum, F. Kuipers, et al. 2002. Bile acid-activated nuclear receptor FXR suppresses apolipopro-tein A-I transcription via a negative FXR response element. J. Clin. Invest. 109: 961-971.